Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles

被引:323
作者
Shen, H
Ackerman, AL
Cody, V
Giodini, A
Hinson, ER
Cresswell, P
Edelson, RL
Saltzman, WM
Hanlon, DJ
机构
[1] Yale Univ, Sch Med, Dept Dermatol, New Haven, CT 06520 USA
[2] Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, New Haven, CT 06520 USA
[3] Yale Univ, Dept Biomed Engn, New Haven, CT 06520 USA
关键词
dendritic cells; antigen presentation/processing; vaccination;
D O I
10.1111/j.1365-2567.2005.02268.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
CD8(+) T-cell responses are critical in the immunological control of tumours and infectious diseases. To prime CD8(+) T cells against these cell-associated antigens, exogenous antigens must be cross-presented by professional antigen-presenting cells (APCs). While cross-presentation of soluble antigens by dendritic cells is detectable in vivo, the efficiency is low, limiting the clinical utility of protein-based vaccinations. To enhance the efficiency of presentation, we generated nanoparticles from a biodegradable polymer, poly(D,L-lactide-co-glycolide) (PLGA), to deliver antigen into the major histocompatibility complex (MHC) class I antigen presentation pathway. In primary mouse bone marrow-derived dendritic cells (BMDCs), the MHC class I presentation of PLGA-encapsulated ovalbumin (OVA) stimulated T cell interleukin-2 secretion at 1000-fold lower concentration than soluble antigen and 10-fold lower than antigen-coated latex beads. The microparticles also served as an intracellular antigen reservoir, leading to sustained MHC class I presentation of OVA for 72 hr, decreasing by only 20% after 96 hr, a time at which the presentation of soluble and latex bead-associated antigens was undetectable. Cytosol extraction demonstrated that antigen delivery via PLGA particles increased the amount of protein that escaped from endosomes into the cytoplasm, thereby increasing the access of exogenous antigen to the classic MHC class I loading pathway. These data indicate that the unique properties of PLGA particle-mediated antigen delivery dramatically enhance and sustain exogenous antigen presentation by MHC class I, potentially facilitating the clinical use of these particles in vaccination.
引用
收藏
页码:78 / 88
页数:11
相关论文
共 63 条
[1]   Cellular mechanisms governing cross-presentation of exogenous antigens [J].
Ackerman, AL ;
Cresswell, P .
NATURE IMMUNOLOGY, 2004, 5 (07) :678-684
[2]   Regulation of MHC class I transport in human dendritic cells and the dendritic-like cell line KG-1 [J].
Ackerman, AL ;
Cresswell, P .
JOURNAL OF IMMUNOLOGY, 2003, 170 (08) :4178-4188
[3]   DIFFERENTIAL TRANSPORT REQUIREMENTS OF HLA AND H-2 CLASS-I GLYCOPROTEINS [J].
ALEXANDER, J ;
PAYNE, JA ;
MURRAY, R ;
FRELINGER, JA ;
CRESSWELL, P .
IMMUNOGENETICS, 1989, 29 (06) :380-388
[4]  
ANDERSON KS, 1993, J IMMUNOL, V151, P3407
[5]   Encapsulation of peptides in biodegradable microspheres prolongs their MHC class-I presentation by dendritic cells and macrophages in vitro [J].
Audran, R ;
Peter, K ;
Dannull, J ;
Men, Y ;
Scandella, E ;
Groettrup, M ;
Gander, B ;
Corradin, G .
VACCINE, 2003, 21 (11-12) :1250-1255
[6]   CROSS-PRIMING FOR A SECONDARY CYTOTOXIC RESPONSE TO MINOR H-ANTIGENS WITH H-2 CONGENIC CELLS WHICH DO NOT CROSS-REACT IN CYTOTOXIC ASSAY [J].
BEVAN, MJ .
JOURNAL OF EXPERIMENTAL MEDICINE, 1976, 143 (05) :1283-1288
[7]   Regulation of phagosome maturation by signals from Toll-like receptors [J].
Blander, JM ;
Medzhitov, R .
SCIENCE, 2004, 304 (5673) :1014-1018
[8]   Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cells [J].
Denis-Mize, KS ;
Dupuis, M ;
MacKichan, ML ;
Singh, M ;
Doe, B ;
O'Hagan, D ;
Ulmer, JB ;
Donnelly, JJ ;
McDonald, DM ;
Ott, G .
GENE THERAPY, 2000, 7 (24) :2105-2112
[9]   Size-dependent immunogenicity: Therapeutic and protective properties of nano-vaccines against tumors [J].
Fifis, T ;
Gamvrellis, A ;
Crimeen-Irwin, B ;
Pietersz, GA ;
Li, J ;
Mottram, PL ;
McKenzie, IFC ;
Plebanski, M .
JOURNAL OF IMMUNOLOGY, 2004, 173 (05) :3148-3154
[10]   Targeting vaccines to dendritic cells [J].
Foged, C ;
Sundblad, A ;
Hovgaard, L .
PHARMACEUTICAL RESEARCH, 2002, 19 (03) :229-238